Altimmune (ALT) Current Assets (2010 - 2026)

Altimmune (ALT) has reported Current Assets for 17 consecutive years, with $334.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 115.56% year-over-year to $334.7 million; the TTM figure through Mar 2026 stood at $334.7 million (up 115.56% YoY), while the FY2025 annual figure was $278.2 million, up 102.68% from the prior year.
• Current Assets grew to $334.7 million in Q1 2026 per ALT's latest filing, from $278.2 million in the prior quarter.
• Across five years, Current Assets topped out at $334.7 million in Q1 2026 and bottomed at $137.3 million in Q4 2024.
• Historically, Current Assets has averaged $194.7 million across 5 years, with a median of $188.4 million in 2025.
• Annual changes were most pronounced in 2024 — Current Assets plunged 34.52% — and 2026, when it jumped 115.56%.
• Altimmune's Current Assets stood at $192.8 million in 2022, then climbed by 8.72% to $209.6 million in 2023, then slumped by 34.52% to $137.3 million in 2024, then jumped by 102.68% to $278.2 million in 2025, then climbed by 20.3% to $334.7 million in 2026.
• Business Quant data shows ALT's Current Assets at $334.7 million in Q1 2026, $278.2 million in Q4 2025, and $216.6 million in Q3 2025.